Kristian Reich
Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, Univ ers ity Medical Center Hamburg Eppendorf, Hamburg, DE
Eric Simpson
Department of Dermatology, Oregon Health & Science University, Portland, OR, USA
Richard Langley
Division of Clinical Dermatology and Cutaneous Science, Dalhousie University, Halifax, Nova Scotia, CA
Richard Warren
Dermatology Centre, Salford Royal NHS Foundation Trust and NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK
Antonio Costanzo
Dermatology Unit Department of Biomedical Sciences, Humanitas University, Milano, IT; Skin Pathology Laboratory, Humanitas Research Hospital IRCCS, Milano, IT
Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, JP
Peter Almgren
LEO Pharma A/S, Ballerup, Denmark
Le Gjerum
LEO Pharma A/S, Ballerup, Denmark
Anna Carlsson
LEO Pharma A/S, Ballerup, Denmark
Melinda Gooderham
SKiN Centre for Dermatology, Peterborough, ON, CA; Department of Dermatology, Queen's University, Kingston, ON, CA; Probity Medical Research, Waterloo, ON, CA;
Andreas Pinter
Department of Dermatology, Venereology, and Allergology, Goethe Universität Frankfurt am Main, Frankfurt am Main, DE
Marjolein De Bruin Weller
Department of Dermatology and Allergology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, NL
Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA
Keywords
atopic dermatitis, tralokinumab
References
1. Nutten S. Ann Nutr Metab. 2015;66(Suppl1):8-16.
2. Weidinger S, Novak N. Lancet. 2016;387:1109-22.
3. Popovic B, et al. J Mol Biol. 2017;429:208-19.
4. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449.
5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463.
6. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3.